IDStewardship

JANUARY 13, 2025

In this article an infectious diseases pharmacist discusses five interesting things to know about sulopenem (Orlynvah). Authored by: Tina Zheng, Pharm.D., BCIDP UNDER CONSTRUCTION Article PostedXXX Sulopenem etzadroxil and probenecid (Orlynvah) was recently approved in October 2024 for the treatment of uncomplicated urinary tract infections (uUTI) caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis.

Packaging 130

Packaging Labelling FDA 130

Pharmacy Times

JANUARY 13, 2025

If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.

FDA 117

FDA 117

Drug Topics

JANUARY 13, 2025

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.

112

112

Pharmacy Times

JANUARY 13, 2025

The new Medicare cap limits out-of-pocket drug costs to $2000 annually.

116

116

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

JANUARY 13, 2025

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its largest events of the year. With the acquisition, the pharma giant will get Intra-Cellular’s Caplyta, which is approved to treat schizophrenia and bipolar-related depression.

107

107

Drug Topics

JANUARY 13, 2025

A conversation with Heather Folz, PharmD, BCACP and Christina H. Sherrill, PharmD, BCACP, BC-ADM.

98

98

Drug Topics

JANUARY 13, 2025

Sarah Gray, PharmD, GAICD, discussed her experience as a pharmacist who added nutrition counseling to her clinical expertise.

98

98

STAT

JANUARY 13, 2025

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of deadlines, online meetings, and the like has predictably returned. Of course, some folks have a more challenging re-entry if they are attending the J.P. Morgan Healthcare Conference, a sort of Woodstock for investors.

FDA 107

FDA 107

Drug Topics

JANUARY 13, 2025

Rite Aid recently released a survey detailing US patients perspective of how they engage with their pharmacists.

98

98

Fierce Healthcare

JANUARY 13, 2025

As deadly fires continue to rage in Los Angeles, healthcare companies far and wide are stepping up to serve those affected. At least 24 people have died from the fires and dozens remain missing.

81

81

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

JANUARY 13, 2025

A combination of ibuprofen and acetaminophen was found to be superior to hydrocodone and acetaminophen in managing pain after impacted mandibular third-molar extraction surgery.

98

98

pharmaphorum

JANUARY 13, 2025

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

81

81

STAT

JANUARY 13, 2025

SAN FRANCISCO — Cigna and Centene have bowed out of this year’s J.P. Morgan Healthcare Conference, a possible sign that leaders of large health care companies are looking to avoid public appearances in light of the assassination of a high-profile executive last month. The health insurance giants are among 11 major companies that dropped out of the industry’s main investor event, according to the final agenda posted by J.P.

Insurance 142

Insurance 142

Pharmacy Times

JANUARY 13, 2025

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

81

81

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

JANUARY 13, 2025

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

80

80

Pharmacy Times

JANUARY 13, 2025

Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.

81

81

Fierce Healthcare

JANUARY 13, 2025

Though largely comprised of nurses, the walk-off that began Friday also includes physician associates and doctorsthe latter of which is a first for Oregon, per the Oregon Nurses Association.

77

77

Pharmacy Times

JANUARY 13, 2025

The designation was supported by data from the phase 2, open-label, randomized, multi-center ARTEMIS-002 clinical trial, which assessed the safety and efficacy of GSK227.

Labelling 81

Labelling FDA 81

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

JANUARY 13, 2025

A recent confluence of events marks the first time in decades that there's been indication of real, meaningful change to the system, writes Blue Shield of California's Matthew Gibbs.

72

72

Pharmacy Times

JANUARY 13, 2025

The Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications.

73

73

Fierce Healthcare

JANUARY 13, 2025

Rock Health's annual report outlines key trends in VC funding: a handful of large, more established players dominated healthcare innovation headlines, heavyweight investors drove sector dealmaking and digital health startups turned to M&A to build out their offerings.

72

72

Pharmaceutical Technology

JANUARY 13, 2025

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

Mayo Clinic 71

Mayo Clinic 71

Fierce Healthcare

JANUARY 13, 2025

SCAN Group will make a strategic investment in Cresta, which has built a generative AI platform for contact centers, the insurer told Fierce Healthcare exclusively.

Insurance 72

Insurance 72

The Checkup by Singlecare

JANUARY 13, 2025

A compounded medication is a custom formulation of an existing brand-name or generic drug made by a licensed pharmacist and designed to meet a patients unique needs. For example, a person who is allergic to a common dye included in a prescription drug could have a compounded version of the drug made without that dye. More notably, compounded drugs are also made to counteract drug shortages.

Compounding 69

Compounding Compounding Pharmacies FDA Insurance Coverage 69

Fierce Healthcare

JANUARY 13, 2025

The annual J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers and dealers to San Francisco.

69

69

pharmaphorum

JANUARY 13, 2025

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

66

66

STAT

JANUARY 13, 2025

LONDON — Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another $150 million in milestone payments, gives GSK an experimental treatment for a rare gastrointestinal cancer.  The announcement comes as much of the biopharma world gathers in San Francisco for the J.P.

115

115

Pharmacy Times

JANUARY 13, 2025

Datopotamab deruxtecan was also granted breakthrough therapy designation in December 2024.

FDA 65

FDA 65

Fierce Healthcare

JANUARY 13, 2025

Artificial intelligence (AI) is at the top of the healthcare buzzword list this year. As we head into a new year with endless potential, its time to find out where the rubber hits the road. | AI is transforming healthcare billing, but how essential is human expertise? Find out how the two should work together in this article from Zelis.

64

64

Pharmacy Times

JANUARY 13, 2025

The proposed age restrictions on dietary supplements would limit consumer access to safe products.

65

65

Fierce Healthcare

JANUARY 13, 2025

The AI task force will release a report on AI-powered ambient scribes and revenue cycle management tools in the first quarter. A goal of the report is to provide guidance to healthcare organizations on how to track the efficacy of the tools.

64

64

Pharmacy Times

JANUARY 13, 2025

Virtual appointments were also an accessible alternative to in-person visits for patients who face obstacles accessing asthma care.

65

65

European Pharmaceutical Review

JANUARY 13, 2025

GSK has agreed to acquire the biopharmaceutical firm IDRx Inc, a company focused on development of precision therapies for gastrointestinal stromal tumours (GIST). The deal is valued up to $1.15 billion, which includes an upfront payment of $1 billion. IDRx Inc could receive a further $150 million, subject to achievement of future regulatory approvals.

59

59